Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Assets (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Non-Current Assets for 10 consecutive years, with $123.6 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 15.7% to $123.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $446.8 million through Dec 2025, up 2.82% year-over-year, with the annual reading at $123.6 million for FY2025, 15.7% up from the prior year.
  • Non-Current Assets for Q4 2025 was $123.6 million at Akebia Therapeutics, up from $105.8 million in the prior quarter.
  • The five-year high for Non-Current Assets was $280.8 million in Q2 2021, with the low at $105.8 million in Q3 2025.
  • Average Non-Current Assets over 5 years is $166.6 million, with a median of $130.3 million recorded in 2023.
  • The sharpest move saw Non-Current Assets tumbled 41.0% in 2021, then rose 15.7% in 2025.
  • Over 5 years, Non-Current Assets stood at $258.2 million in 2021, then tumbled by 33.82% to $170.9 million in 2022, then fell by 27.69% to $123.6 million in 2023, then decreased by 13.53% to $106.8 million in 2024, then increased by 15.7% to $123.6 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $123.6 million, $105.8 million, and $110.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.